Asthma

Nanoparticle

Cisplatin

Pharmacokinetics

Materials science

Inhaler

Lung cancer

Cancer research

Biochemistry

Anesthesia

Inhalation

Nanotechnology

In vitro

Internal medicine

Pharmacology

Chemotherapy

Oncology

IC50

Medicine

Chemistry

Dry-powder inhaler

Efflux

Pathology

Therapeutic Delivery

Background: The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin and siRNA for multidrug-resistant lung cancer. siRNA against ABCC3 gene was used to silence drug efflux promoter. Results & discussion: The formulation was optimized through the quality by design system by nanoparticle size and cisplatin entrapment. The lipid concentration, polymer concentration and lipid molar ratio were selected as variables. The DPI was characterized by in vitro deposition study using the Anderson cascade impactor. DPI formulation showed improved pulmonary pharmacokinetic parameters of cisplatin with higher residence time in lungs. Conclusion: Local delivery of siRNA and cisplatin to the lung tissue resulted into an enhanced therapeutic effectiveness in combating drug resistance.

Development of a Dry Powder for Inhalation of Nanoparticles Codelivering Cisplatin and <i>ABCC3</i> siRNA in Lung Cancer

Development of a Dry Powder for Inhalation of Nanoparticles Codelivering Cisplatin and ABCC3 siRNA in Lung Cancer